Vertex Pharmaceuticals Stock News

Amazon has formidable moats and multiple avenues for growth. Enbridge offers stability, a generous dividend, and growth opportunities related to AI.

Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.

Vertex Pharmaceuticals Incorporated ( VRTX ) UBS Global Healthcare Conference 2025 November 11, 2025 10:15 AM EST Company Participants Reshma Kewalramani - CEO, President & Director Conference Call Participants Dina Elmonshed Presentation Dina Elmonshed Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS.

Vertex Pharmaceuticals Incorporated ( VRTX ) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio November 8, 2025 8:00 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Conference Call Participants James A. Tumlin Richard Lafayette Brad Rovin Carter Gould - Cantor Fitzgeral...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic and dual inhibitor of the...

During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campaigns in Atlassian, Adidas and Vertex Pharmaceuticals during the quarter.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities across its pipeline. JOURNAVX drives revenue with strong acute pain demand and is advancing into diabetic peripheral neuropathy (DPN) with two phase 3 studies enrolling through 2026. VRTX's BAFF/APRIL inhibitor povetacicept offers a 'pipeline in a pill' approach, targeting ...

Electronic Arts' shares outperformed the broader market during the period, driven by renewed investor confidence and momentum surrounding several high-profile product announcements. eBay's shares surged after reporting a strong second-quarter earnings report, bolstering confidence in the company's position in the marketplace. Elevance Health was the top underperformer over the period. Much of t...